| Literature DB >> 32382285 |
Shen Zhao1,2, Ziren Tang3,4, Hao Cui3, Zhengfei Yang5, Fei Shao3, Shuo Wang3, Feng Chen1,2.
Abstract
OBJECTIVE: To comprehensively evaluate the protective effect of Shenfu injection (SFI) on renal ischaemia/reperfusion injury (IRI) after cardiopulmonary resuscitation (CPR) through neutrophil gelatinase-associated lipocalin (NGAL) and to explore effective monitoring of early renal injuries after CPR.Entities:
Year: 2020 PMID: 32382285 PMCID: PMC7193270 DOI: 10.1155/2020/3789268
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Haematoxylin and eosin (H&E) staining. The animals underwent CPR displayed signs of kidney damage with HE staining, including congestion in the renal tubular and glomerular capillaries, mesangial hyperplasia, inflammatory cell infiltration, and microthrombus formation in the renal arterioles (b) and (c). The renal injury in the SFI group was significantly reduced compared to that in the control group (c), whereas no obvious damage was found in the kidney pathology of the animals in the SO group (a). (a) The Sham operation group. (b) The control group. (c) The SFI group.
Figure 2TDT-mediated biotinylated dUTP nick end-labelling (TUNEL). The apoptotic cells were stained with brown. Compared with that of the SO group, the AI of the control and SFI groups increased significantly (P < 0.01). Furthermore, when we compared the AI between the control and SFI groups, the AI of the SFI group was significantly reduced (P < 0.01). (a) The Sham operation group. (b) The control group. (c) The SFI group.
Changes in renal function.
| Groups | Baseline state | 2 hr | 6 hr | 12 hr | 24 hr |
|---|---|---|---|---|---|
| Urine volume (mL/kg/hr) | |||||
| SO | 1.01 ± 0.12 | 1.00 ± 0.13 | 1.12 ± 0.12 | 1.14 ± 0.11 | 1.13 ± 0.13 |
| Control | 1.02 ± 0.11 | 0.41 ± 0.17 | 0.42 ± 0.19 | 0.39 ± 0.20 | 0.36 ± 0.21 |
| SFI | 0.99 ± 0.13 | 0.42 ± 0.15 | 0.87 ± 0.17 | 0.89 ± 0.16 | 0.93 ± 0.16 |
|
| |||||
| Serum creatinine (sCr, | |||||
| SO | 62.12 ± 6.04 | 63.12 ± 5.36 | 61.26 ± 6.22 | 62.74 ± 5.68 | 63.54 ± 6.05 |
| Control | 63.24 ± 5.39 | 62.66 ± 6.98 | 66.45 ± 6.13 | 67.39 ± 7.12 | 67.12 ± 6.98 |
| SFI | 65.19 ± 5.39 | 61.34 ± 5.89 | 63.16 ± 6.61 | 66.13 ± 5.29 | 66.45 ± 6.01 |
|
| |||||
| Serum NGAL (sNGAL, ng/mL) | |||||
| SO | 2.18 ± 0.12 | 2.21 ± 0.15 | 2.20 ± 0.13 | 2.19 ± 0.15 | 2.21 ± 0.16 |
| Control | 2.21 ± 0.11 | 4.11 ± 0.20 | 6.66 ± 0.19 | 8.19 ± 0.20 | 10.11 ± 0.15 |
| SFI | 2.19 ± 0.12 | 3.12 ± 0.21 | 4.19 ± 0.18 | 4.36 ± 0.21 | 4.79 ± 0.22 |
|
| |||||
| Urine NGAL (uNGAL, ng/mL) | |||||
| SO | 0.49 ± 0.04 | 0.51 ± 0.07 | 0.50 ± 0.06 | 0.49 ± 0.05 | 0.52 ± 0.06 |
| Control | 0.50 ± 0.05 | 1.82 ± 0.09 | 4.45 ± 0.10 | 5.64 ± 0.12 | 6.87 ± 0.11 |
| SFI | 0.47 ± 0.06 | 1.43 ± 0.08 | 1.99 ± 0.10 | 2.01 ± 0.11 | 2.14 ± 0.12 |
P < 0.05 compared with the SO group; P < 0.01 compared with the SO group; #P < 0.05 compared with the control group; ##P < 0.05 compared with the control group.
Figure 3Western Blotting. The Bax and activated caspase-3 expression levels in the kidneys were significantly higher than those in the SO group. The Bcl-2 and Bcl-2/Bax levels were both significantly decreased (P < 0.01). The Bax and activated caspase-3 expression levels in the SFI group were also clearly reduced compared to those in the control group, whereas the Bcl-2 and Bcl-2/Bax expression levels were significantly increased by SFI (P < 0.05). Versus the SO group, P < 0.01; #vs. the control group, P < 0.05.
Haemodynamic parameters.
| Groups | Baseline state | 2 hr | 6 hr | 12 hr | 24 hr |
|---|---|---|---|---|---|
| HR, times/min | |||||
| SO | 110 ± 12 | 121 ± 18 | 112 ± 15 | 111 ± 15 | 112 ± 15 |
| Control | 107 ± 13 | 135 ± 22 | 132 ± 16 | 131 ± 17 | 138 ± 16 |
| SFI | 109 ± 15 | 136 ± 19 | 134 ± 14 | 132 ± 19 | 135 ± 11 |
|
| |||||
| MAP, mmHg | |||||
| SO | 96 ± 6 | 99 ± 8 | 94 ± 9 | 94 ± 10 | 95 ± 9 |
| Control | 95 ± 5 | 75 ± 15 | 77 ± 17 | 75 ± 16 | 72 ± 15 |
| SFI | 94 ± 7 | 79 ± 13 | 86 ± 17# | 87 ± 15# | 86 ± 14# |
|
| |||||
| CPP | |||||
| SO | 90 ± 9 | 93 ± 11 | 91 ± 10 | 92 ± 11 | 90 ± 12 |
| Control | 89 ± 8 | 66 ± 15 | 67 ± 16 | 67 ± 14 | 66 ± 15 |
| SFI | 88 ± 8 | 70 ± 13 | 80 ± 11 | 81 ± 12 | 80 ± 10 |
|
| |||||
| CO, L/min | |||||
| SO | 3.3 ± 0.3 | 3.5 ± 0.4 | 3.2 ± 0.2 | 3.4 ± 0.3 | 3.1 ± 0.4 |
| Control | 3.1 ± 0.5 | 2.3 ± 0.9 | 2.2 ± 0.8 | 2.3 ± 0.7 | 2.3 ± 0.6 |
| SFI | 3.2 ± 0.4 | 2.4 ± 0.4 | 2.7 ± 0.5 | 2.9 ± 0.4 | 3.0 ± 0.5# |
|
| |||||
| Systemic vascular resistance (SVR) | |||||
| SO | 1050 ± 114 | 1201 ± 143 | 1198 ± 132 | 1212 ± 144 | 1184 ± 153 |
| Control | 1102 ± 121 | 1984 ± 225 | 2126 ± 276 | 2381 ± 366 | 2471 ± 343 |
| SFI | 1121 ± 131 | 1795 ± 302 | 2035 ± 249 | 2015 ± 328 | 2004 ± 336 |
P < 0.05 compared with the SO group; P < 0.01 compared with the SO group; #P < 0.05 compared with the control group; ##P < 0.01 compared with the control group.